Johnson & Johnson (J&J) announced its first-quarter 2026 financial results on April 18, reporting performance that exceeded internal and external projections. The healthcare conglomerate raised its full-year 2026 revenue guidance to a range of $100.5 billion to $100.8 billion, up from previous estimates. This adjustment reflects sustained momentum in its Innovative Medicine division and steady gains in its MedTech segment.
For the quarter ended March 31, 2026, J&J reported total sales of $24.1 billion, representing a 6.8% increase compared to the same period in 2025. Adjusted operational growth, which excludes the impact of currency fluctuations, stood at 7.4%. The company reported adjusted diluted earnings per share (EPS) of $2.82, surpassing the consensus estimate of $2.74. Chief Financial Officer Joseph Wolk attributed the financial strength to disciplined cost management and the successful integration of recent acquisitions.
The Innovative Medicine segment, formerly known as Janssen, remained the primary growth engine, generating $14.9 billion in quarterly revenue. Oncology sales were particularly robust, led by the continued market expansion of Darzalex and the scaling of the cell therapy Carvykti. In the immunology sector, Tremfya saw double-digit growth as it secured additional indications, while Stelara maintained a resilient market share despite the entry of biosimilar competition in certain international markets. The company noted that its pipeline of late-stage assets remains on track for multiple regulatory filings later this year.
The MedTech division reported sales of $9.2 billion, a 5.5% increase year-over-year. Growth was driven by the cardiovascular portfolio, specifically electrophysiology products and the Abiomed heart pump line. J&J also highlighted the impact of its recently launched surgical robotics platforms, which have begun to see broader adoption in North American and European hospitals. The segment benefited from a recovery in elective procedure volumes and the introduction of new orthopedic technologies.
Chief Executive Officer Joaquin Duato stated that the first-quarter results demonstrate the company's ability to navigate a complex global healthcare environment while investing in long-term innovation. Duato emphasized that the upward revision of the full-year outlook is supported by the strength of the current product portfolio and the anticipated launch of several new molecular entities. The company confirmed it remains committed to its 2030 growth targets, which include reaching $57 billion in pharmaceutical sales by the end of the decade. J&J also maintained its quarterly dividend of $1.24 per share, which was announced earlier in the month.